Arrhythmogenic Right Ventricular Cardiomyopathy

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a primary myocardial disease characterized by progressive fibrofatty replacement of the right ventricular myocardium, leading to ventricular arrhythmias, right ventricular systolic dysfunction, and sudden cardiac death. In veterinary medicine, ARVC is most commonly recognized in Boxer dogs, where it is often referred to as Boxer cardiomyopathy. The disease is considered a form of inherited cardiomyopathy, with an autosomal dominant pattern of inheritance in some breeds. The pathological hallmark is the substitution of viable myocardium with adipose and fibrous tissue, which disrupts electrical conduction and creates a substrate for reentrant arrhythmias. Clinically, ARVC manifests as ventricular premature complexes (VPCs), ventricular tachycardia (VT), syncope, and in severe cases, congestive heart failure (CHF) or sudden death. The disease is progressive, and the clinical course varies from asymptomatic arrhythmias to severe myocardial failure.

The exact etiology of ARVC in dogs is not fully understood, but a strong genetic basis is recognized. In Boxer dogs, ARVC is inherited as an autosomal dominant trait with variable penetrance. Mutations in genes encoding desmosomal proteins, such as plakoglobin, desmoplakin, and plakophilin-2, have been identified in human ARVC and are suspected in canine cases. These proteins are critical for cell-to-cell adhesion in the myocardium, and their dysfunction leads to myocyte death and fibrofatty replacement. In addition to genetic factors, inflammatory and infectious triggers have been proposed, but no specific viral or bacterial agent has been consistently implicated. Environmental factors, such as intense athletic training, may exacerbate the phenotype in predisposed individuals. The disease is not considered contagious or toxic in origin.

ARVC is most prevalent in Boxer dogs, with a reported incidence of up to 30% in some populations. It is also recognized in other breeds, including Bulldogs, German Shepherds, and occasionally in cats, though less commonly. The disease typically manifests in middle-aged to older dogs, with a mean age of onset around 6 to 8 years. Both sexes are affected, but some studies suggest a slight male predominance. There is no geographic predilection, but the disease is more commonly diagnosed in breeds with a high prevalence of the genetic mutation. In Boxers, the disease is a leading cause of sudden cardiac death, particularly in dogs used for working or athletic purposes. The prevalence in other breeds is less well-documented, but sporadic cases are reported.

The pathophysiology of ARVC involves progressive myocyte loss and replacement by fibrofatty tissue, primarily affecting the right ventricular free wall, but also the interventricular septum and left ventricle in advanced cases. The initial insult is believed to be genetic, leading to dysfunction of desmosomal proteins and impaired cell-to-cell adhesion. This results in myocyte detachment and apoptosis, particularly under conditions of mechanical stress. The subsequent inflammatory response and fibrosis create areas of electrical inhomogeneity, which serve as substrates for reentrant arrhythmias. The arrhythmias are typically exercise-induced or exacerbated by catecholamines. As the disease progresses, right ventricular systolic function declines, leading to right-sided heart failure, characterized by ascites, hepatomegaly, and peripheral edema. In some cases, left ventricular involvement can occur, leading to biventricular failure. The arrhythmias can degenerate into ventricular fibrillation, causing sudden death.

The primary predisposing factor is genetic susceptibility, particularly in Boxer dogs with a family history of ARVC. Age is a significant factor, as the disease typically manifests in middle-aged to older dogs. Sex may play a role, with males being slightly overrepresented. Environmental factors, such as intense physical exertion or stress, can precipitate arrhythmias and accelerate disease progression. Concurrent cardiac diseases, such as mitral valve disease or dilated cardiomyopathy, may complicate the clinical picture. The use of certain drugs, such as sympathomimetics, can exacerbate arrhythmias. Obesity and poor physical conditioning may also contribute to the severity of clinical signs.

Clinical signs of ARVC vary depending on the stage of the disease. In the early stages, dogs may be asymptomatic, with arrhythmias detected incidentally on routine examination. As the disease progresses, common signs include exercise intolerance, weakness, syncope, and episodes of collapse. Syncope is often associated with ventricular tachycardia or asystole. In advanced stages, signs of right-sided congestive heart failure may develop, including abdominal distension due to ascites, jugular venous distension, hepatomegaly, and peripheral edema. Some dogs may present with signs of left-sided heart failure, such as cough and dyspnea, if left ventricular involvement is significant. Sudden cardiac death can occur without prior clinical signs, particularly in young to middle-aged Boxers. Physical examination may reveal cardiac arrhythmias, such as premature beats or tachycardia, and a pulse deficit. Heart murmurs are uncommon unless concurrent valvular disease is present.

Differential diagnoses for ARVC include other causes of ventricular arrhythmias and syncope, such as dilated cardiomyopathy (DCM), myocarditis, myocardial infarction, and electrolyte imbalances. DCM is a common differential, especially in large breed dogs, and can be differentiated by echocardiographic findings of left ventricular dilation and systolic dysfunction. Myocarditis, often due to infectious agents or immune-mediated disease, may present with acute onset of arrhythmias and can be diagnosed by cardiac biomarkers, PCR, or histopathology. Myocardial infarction is rare in dogs but can cause arrhythmias and regional wall motion abnormalities. Electrolyte imbalances, particularly hypokalemia and hypomagnesemia, can predispose to arrhythmias and should be ruled out. Other causes of syncope, such as vasovagal syncope, pulmonary hypertension, and aortic stenosis, should also be considered. In Boxers, ARVC must be differentiated from other inherited cardiomyopathies, such as DCM, which can have overlapping features.

The diagnostic algorithm for ARVC begins with a thorough history and physical examination, with particular attention to cardiac auscultation and pulse quality. If arrhythmias are suspected, a resting electrocardiogram (ECG) should be performed. A 24-hour Holter monitor is the gold standard for quantifying ventricular arrhythmias and is recommended for all Boxers with suspected ARVC, as it can detect arrhythmias that are not present on a short ECG. Echocardiography is essential to assess right ventricular size and function, as well as to rule out other structural heart diseases. In early ARVC, echocardiography may be normal, but as the disease progresses, right ventricular dilation and reduced systolic function may be observed. Cardiac biomarkers, such as cardiac troponin I and NT-proBNP, may be elevated and can support the diagnosis. In some cases, cardiac magnetic resonance imaging (MRI) can detect fibrofatty infiltration, but this is rarely performed in veterinary practice. Genetic testing for known mutations is available for Boxers and can aid in diagnosis and breeding decisions. A definitive diagnosis is based on the presence of characteristic arrhythmias, echocardiographic findings, and histopathology if available.

Routine laboratory findings in ARVC are often unremarkable. Complete blood count (CBC) may show stress leukogram or no abnormalities. Serum biochemistry may reveal mild elevations in liver enzymes due to hepatic congestion in cases of right-sided heart failure. Electrolyte imbalances, particularly hypokalemia and hypomagnesemia, should be evaluated as they can exacerbate arrhythmias. Cardiac biomarkers, such as cardiac troponin I (cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), may be elevated, indicating myocardial injury and stretch, respectively. In dogs with heart failure, NT-proBNP is typically elevated. Genetic testing for ARVC-associated mutations can be performed on blood or buccal swabs. Urinalysis is usually normal unless concurrent disease is present.

Echocardiography is the primary imaging modality for ARVC. In early stages, the right ventricle may appear normal, but as the disease progresses, right ventricular dilation, reduced right ventricular systolic function, and increased right ventricular wall echogenicity may be observed. The right atrium may also be enlarged. In advanced cases, left ventricular involvement may be seen, with reduced left ventricular systolic function. Thoracic radiography may show cardiomegaly, particularly right-sided enlargement, and signs of congestive heart failure, such as pulmonary edema or pleural effusion, in advanced cases. However, radiography is not sensitive for early ARVC. Cardiac MRI is the gold standard for detecting fibrofatty infiltration in humans, but its use in veterinary medicine is limited due to cost and availability. Computed tomography (CT) is not commonly used for ARVC diagnosis.

Histopathology is the definitive diagnostic method for ARVC, but it is rarely performed antemortem. Postmortem examination reveals fibrofatty replacement of the right ventricular myocardium, with myocyte atrophy and fibrosis. The lesions are typically most severe in the right ventricular free wall, but can extend to the interventricular septum and left ventricle. Inflammatory infiltrates may be present in some cases. Histochemical stains, such as Masson's trichrome, can highlight fibrosis, and Oil Red O can stain adipose tissue. Cytology is not typically used for diagnosis, as the disease is not characterized by effusions or masses that would be amenable to fine-needle aspiration.

Treatment of ARVC aims to control arrhythmias, manage heart failure if present, and reduce the risk of sudden death. Antiarrhythmic therapy is indicated for dogs with symptomatic arrhythmias, such as syncope, or those with high-grade ventricular arrhythmias on Holter monitoring. Sotalol is often the first-line antiarrhythmic in Boxers with ARVC, at a dose of 1.5-3.5 mg/kg PO q12h. Mexiletine can be added for refractory cases, at a dose of 4-8 mg/kg PO q8h. Amiodarone is reserved for severe cases due to its potential for toxicity, at a dose of 10-15 mg/kg PO q12h for 7 days, then 5-10 mg/kg PO q24h. Beta-blockers, such as atenolol, may be used if sotalol is not tolerated, at a dose of 0.25-1 mg/kg PO q12h. In dogs with heart failure, standard therapy includes furosemide (1-2 mg/kg PO q8-12h), pimobendan (0.25-0.3 mg/kg PO q12h), and an ACE inhibitor such as enalapril (0.5 mg/kg PO q12h). Exercise restriction is recommended to reduce the risk of arrhythmias. In cases of refractory arrhythmias, catheter ablation or implantable cardioverter-defibrillators (ICDs) are options, but these are rarely performed in veterinary practice.

The prognosis for ARVC is variable. Dogs with asymptomatic arrhythmias may live for years with appropriate management. However, the risk of sudden death is significant, particularly in dogs with high-grade ventricular arrhythmias or a history of syncope. The development of congestive heart failure carries a guarded prognosis, with a median survival time of several months to a year. Negative prognostic indicators include the presence of syncope, high ventricular arrhythmia burden (e.g., >1000 VPCs/24h), reduced right ventricular systolic function, and the development of heart failure. With treatment, many dogs can have a good quality of life for a period, but the disease is progressive and ultimately fatal.

Follow-up for dogs with ARVC should include regular re-evaluations every 3-6 months, depending on the severity of the disease. A 24-hour Holter monitor should be repeated every 3-6 months to assess arrhythmia burden and response to therapy. Echocardiography should be repeated every 6-12 months to monitor right ventricular size and function. Serum cardiac biomarkers, such as NT-proBNP, can be monitored to assess the progression of heart failure. Owners should be educated to monitor for signs of syncope, weakness, or exercise intolerance, and to seek immediate veterinary care if these occur. Dose adjustments of antiarrhythmic medications should be based on Holter results and clinical signs. In dogs with heart failure, regular monitoring of renal function and electrolytes is necessary when using diuretics and ACE inhibitors.

Pearls: 1) ARVC should be suspected in any Boxer dog with ventricular arrhythmias, even if asymptomatic. 2) A 24-hour Holter monitor is essential for accurate arrhythmia assessment, as a short ECG may miss intermittent arrhythmias. 3) Sotalol is the preferred antiarrhythmic in Boxers with ARVC due to its combined beta-blocking and class III antiarrhythmic effects. 4) Exercise restriction is important to reduce the risk of arrhythmias. Pitfalls: 1) Failure to perform a Holter monitor may lead to underestimation of arrhythmia severity. 2) Using antiarrhythmics without addressing underlying heart failure can worsen clinical signs. 3) Overdosing with antiarrhythmics can cause proarrhythmia or negative inotropic effects. 4) Ignoring the potential for sudden death and failing to counsel owners about this risk.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: Sotalol: 1.5-3.5 mg/kg PO q12h. Mexiletine: 4-8 mg/kg PO q8h. Amiodarone: 10-15 mg/kg PO q12h for 7 days, then 5-10 mg/kg PO q24h. Atenolol: 0.25-1 mg/kg PO q12h. Furosemide: 1-2 mg/kg PO q8-12h, adjust based on renal function. Pimobendan: 0.25-0.3 mg/kg PO q12h. Enalapril: 0.5 mg/kg PO q12h. All dosages should be adjusted based on individual patient response and renal/hepatic function. Contraindications include the use of sotalol in dogs with pre-existing bradycardia or heart block. Drug interactions: sotalol and amiodarone can potentiate QT prolongation; mexiletine should be used with caution with other antiarrhythmics.

The ACVIM consensus statement on the diagnosis and treatment of canine arrhythmogenic right ventricular cardiomyopathy provides guidelines for diagnosis and management. Studies have shown that sotalol is effective in reducing ventricular arrhythmias in Boxers with ARVC. A study by Meurs et al. (2000) identified a genetic mutation in the plakophilin-2 gene in Boxers with ARVC. Another study by Spier and Meurs (2004) evaluated the use of Holter monitoring in Boxers and found that >100 VPCs/24h is a significant predictor of sudden death. The use of amiodarone has been studied in refractory cases, but its use is limited by potential toxicity. The prognosis for dogs with ARVC and heart failure is poor, with a median survival time of less than 6 months in some studies. Overall, the literature supports the use of sotalol as first-line therapy, with mexiletine as an add-on, and emphasizes the importance of Holter monitoring for risk stratification.